ReviewThe oncologist2014
New oral anticoagulants and the cancer patient.
Review in The oncologist, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Net clinical benefit of DOACs vs. usual anticoagulation treatment in venous thromboembolism and active cancer: systematic review and meta-analysis.Journal of thrombosis and thrombolysis · 2023Pooled it
- Incidence of stroke in the first year after diagnosis of cancer-A systematic review and meta-analysis.Frontiers in neurology · 2022Pooled it
- Visceral Thromboses in Pancreas Adenocarcinoma: Systematic Review.Clinical colorectal cancer · 2018Pooled it
- Can thromboprophylaxis build a link for cancer patients undergoing surgical and/or chemotherapy treatment? The MeTHOS cohort study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Trial
- Article
- Direct oral anticoagulants versus low-molecular-weight heparin for thromboprophylaxis in cancer-related surgeries: A meta-analysis of efficacy and safety outcomes.American heart journal plus : cardiology research and practice · 2025Review
- Clinical Challenges in Treating Cancer-Associated Thrombosis: A Clinically Oriented Review.Acta haematologica · 2025Review
- Elevated Platelet Aggregation in Patients with Ovarian Cancer: More than Just Increased Platelet Count.Cancers · 2024Article
- The Role of Injectables in the Treatment and Prevention of Cancer-Associated Thrombosis.Cancers · 2023Review
- Treatment of Cancer-Associated Thrombosis: Recent Advances, Unmet Needs, and Future Direction.The oncologist · 2023Article
- Clinical trial assessing the safety of edoxaban with concomitant chemotherapy in patients with gynecological cancer-associated thrombosis (EGCAT study).Thrombosis journal · 2023Article
- Review
- Cancer-Associated Thrombosis: A Taiwanese Perspective on Therapeutic Options with Focus on Non-Vitamin K Antagonist Oral Anticoagulants.Acta Cardiologica Sinica · 2023Review
- Construction and validation of a nomogram of risk factors for new-onset atrial fibrillation in advanced lung cancer patients after non-surgical therapy.Frontiers in oncology · 2023Article
- The 5 most frequently asked questions about factor Xa inhibitors.Hematology. American Society of Hematology. Education Program · 2022Article
- Complexity and clinical significance of drug-drug interactions (DDIs) in oncology: challenging issues in the care of patients regarding cancer-associated thrombosis (CAT).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Review
- Practical Considerations for the Management of Cancer-Associated Venous Thromboembolism: A Guide for the General Oncology Practitioner.Current oncology (Toronto, Ont.) · 2022Review
- Hemorrhage Risk Among Patients With Breast Cancer Receiving Concurrent Direct Oral Anticoagulants With Tamoxifen vs Aromatase Inhibitors.JAMA network open · 2022Article
- Are outpatient anticoagulation management services the wave of the future (again)?Research and practice in thrombosis and haemostasis · 2022Article
- Risk of major bleeding associated with concomitant use of anticancer drugs and direct oral anticoagulant in patients with cancer and atrial fibrillation.Journal of thrombosis and thrombolysis · 2022Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Indications for anticoagulation are common in patients with malignancy. Cancer patients have an increased risk of developing venous thromboembolic events or may have other indications for anticoagulation, such as atrial fibrillation. New oral anticoagulants (NOACs) are now available that offer increased options for anticoagulation beyond the traditional vitamin K antagonists and low molecular weight heparins that have long been the cornerstone of treatment. This review will focus on the three NOACs that are currently approved for use in the U.S.: the direct thrombin inhibitor, dabigatran, and the factor Xa inhibitors, apixaban and rivaroxaban. Oncologists are likely to encounter an increasing number of patients taking these agents at the time of their cancer diagnosis or to have patients who develop indications for anticoagulation during the course of their disease. The basic pharmacology, current clinical indications, and approach to the use of NOACs in the cancer patient will be reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.